Merrill maintains Amylin at neutral

Amylin Pharmaceuticals Inc. was kept at its neutral rating by Merrill Lynch analyst Thomas McGahren on news that Amylin and Eli Lilly have filed a supplemental New Drug Application to expand the Byetta label to include its use in combination with oral thiazolidinediones in patients with type 2 diabetes who are not achieving adequate glucose control on TZDs or TZD plus metformin. Merrill's model anticipates approval of the expanded label and forecasts U.S. Byetta sales at $342 million in 2006, $546 million in 2007 and $725 million in 2008. Shares of the San Diego pharmaceutical company were down 11 cents, or 0.25%, at $43.79 on volume of 1,078,518 shares versus the three-month running average of 2,029,700 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.